In the past week, NTLA stock has gone up by 17.76%, with a monthly gain of 10.97% and a quarterly plunge of -21.84%. The volatility ratio for the week is 4.38%, and the volatility levels for the last 30 days are 7.59% for Intellia Therapeutics Inc The simple moving average for the past 20 days is -3.40% for NTLA’s stock, with a -37.99% simple moving average for the past 200 days.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
The stock has a 36-month beta value of 2.13. Opinions on the stock are mixed, with 18 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for NTLA is 97.48M, and at present, short sellers hold a 31.50% of that float. On June 09, 2025, the average trading volume of NTLA was 4.01M shares.
NTLA) stock’s latest price update
The stock of Intellia Therapeutics Inc (NASDAQ: NTLA) has increased by 6.73 when compared to last closing price of 7.58. Despite this, the company has experienced a 17.76% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-05 that CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Wolfe Research repeating the rating for NTLA by listing it as a “Outperform.” The predicted price for NTLA in the upcoming period, according to Wolfe Research is $21 based on the research report published on April 21, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $30. The rating they have provided for NTLA stocks is “Buy” according to the report published on March 05th, 2025.
JP Morgan gave a rating of “Neutral” to NTLA, setting the target price at $13 in the report published on February 28th of the current year.
NTLA Trading at 1.97% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.29% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Bhanji Muna, who sale 265 shares at the price of $8.50 back on Apr 29 ’25. After this action, Bhanji Muna now owns 19,203 shares of Intellia Therapeutics Inc, valued at $2,252 using the latest closing price.
Clark Eliana, the EVP, Chief Technical Officer of Intellia Therapeutics Inc, sale 679 shares at $8.99 during a trade that took place back on Mar 04 ’25, which means that Clark Eliana is holding 95,369 shares at $6,104 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -11.87 for the present operating margin
- 0.89 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -11.54. The total capital return value is set at -0.62. Equity return is now at value -57.92, with -46.84 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.16.
Currently, EBITDA for the company is -523.98 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 18.22. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To sum up, Intellia Therapeutics Inc (NTLA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
